<DOC>
	<DOCNO>NCT02544425</DOCNO>
	<brief_summary>Open-labeled , multicenter phase II study VIDL ( VP-16 , Ifosfamide , Dexamethasone , L-asparaginase ) chemotherapy follow high-dose chemotherapy autologous stem cell transplantation patient stage III/IV extranodal NK/T-cell Lymphoma .</brief_summary>
	<brief_title>VP-16 , Ifosfamide , Dexamethasone , L-asparaginase Chemotherapy Patients With Extranodal Natural Killer T Cell Lymphoma ( VIDL+ASCT )</brief_title>
	<detailed_description>Extranodal NK/T cell lymphoma ( ENKTL ) rare aggressive lymphoma subtype , standard front-line therapy establish . The clinical outcome patient ( pt ) ENKTL treatment conventional chemotherapy , especially pt advanced stage , generally poor . Therefore , high-dose chemotherapy follow autologous stem cell transplantation ( ASCT ) consolidation could one promising strategy improve outcome ENKTL . However , study report survival outcome prognostic significance front-line ASCT pt ENKTL . Thus , aim study investigate outcome patient advanced-stage ENKTL undergone front-line ASCT .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Histologically confirm extranodal NK/T cell lymphoma Aged 19 65 year Previously untreated history Performance status : Eastern Cooperative Oncology Group 02 Ann Arbor stage III IV At least one positron emission tomograph ( PET ) /CT positive lesion 2dimensional computerized tomography mass lesion 2 cm conventional CT 1 cm spiral CT Skin lesion physically detect mass 2 cm Cardiac ejection fraction ≥ 45 % measure multiple gated acquisition scan ( MUGA ) 2D echogram ( ECHO ) without clinically significant abnormality Adequate liver function : Transaminase ( AST/ALT ) &lt; 3 X upper normal value ( &lt; 5 x upper limit normal presence NK/T lymphoma involvement liver ) Bilirubin &lt; 2 X upper normal value ( &lt; 5 x upper limit normal presence DLBCL involvement liver ) Serum Creatinine &lt; 2.0 mg/dL Adequate bone marrow function : hemoglobin ≥ 9 g/dL absolute neutrophil count ( ANC ) ≥ 1,500/μL platelet count ≥ 75,000/μL , unless abnormality due bone marrow involvement lymphoma Expected life 180 day ( 6 month ) A negative serum urine pregnancy test prior treatment must available premenopausal woman woman &lt; 1years onset menopause . Premenopausal woman treat appropriate contraception hormone contraception , intrauterine device , spermicidal condom etc . one month treatment . Voluntarily sign informed consent include fully understand clinical procedure process step clinical trial Patients serious medical condition , abnormal laboratory result psychiatric problem Other subtypes nonHodgkin 's lymphoma NK/T cell lymphoma Patients aggressive NK/T cell leukemia NK/T cell lymphoma Primary Central Nervous System ( CNS ) involvement . However , patient prophylactic intrathecal chemotherapy CNS disease eligible . Patients known history HIV seropositivity hepatitis C virus ( HCV ) ( + ) . Patients carrier hepatitis B virus ( HBV ) ( + ) eligible . However , primary prophylaxis use antiviral agent recommend HBV carrier prevent HBV reactivation whole treatment period . Any malignancy within past 5 year except curatively treat nonmelanoma skin cancer situ carcinoma cervix uteri Pregnant lactate woman , woman childbearing potential employ adequate contraception Other serious illness medical condition i. Unstable cardiac disease despite treatment , myocardial infarction within 6 month prior study entry ii . History significant neurologic psychiatric disorder include dementia seizure iii . Active uncontrolled infection ( viral , bacterial fungal infection ) iv . Other serious medical illness Concomitant administration experimental drug investigation , concomitant chemotherapy , hormonal therapy , immunotherapy . Serious allergy history experimental drug Patients contraindication study drug use</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>